Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4604 in adults with uncontrolled moderate-to-severe asthma
NL-OMON59861Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing AZD4604 plus background therapy with Placebo plus background therapy (2 arms). Primary endpoint: Time to first CompEx event. Started Nov 2023; status: completed.
02
Drugs
londamocitinib
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON59861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59861.